Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Actegy Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
To investigate the efficacy of an electrical stimulation (using the REVITIVE IX device) in treating patients with venous insufficiency.
This is a pilot randomised control trial to assess the efficacy of a neuromuscular electrical stimulation device to improve venous blood flow and patients' symptoms in patients with chronic venous insufficiency. The Revitive IX device is a neuromuscular electrical stimulation device that gives wide pulse pattern electrical stimulation via foot pads. A cycle of treatment consists of a 30 minute programme of 15 varying waveforms that last a minute each.
Twenty patients with venous insufficiency will be screened according the eligibility criteria. Patients will be randomised to either treatment or control (sham device) group. Patients are advised to use the device 30 minutes a day, everyday, for 6 weeks. Compliance will be monitored with a data logger and diary card.
Primary outcome measure:
a) improvement in venous haemodynamics.
Secondary outcome measures:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| REVITIVE IX: actual device | Active Comparator | Trial participants will receive the true Revitive IX device |
|
| REVITIVE IX: sham device | Sham Comparator | Trial participants will receive a sham device |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| REVITIVE IX | Device | neuromuscular electrical stimulation device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV | Femoral vein haemodynamics is measured using ultrasound scan - Time Averaged Mean Velocity | 0 and 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Limb Swelling, Volume | Lower limb oedema measured before and after using the device at 0 and 6 weeks using a perimeter. Limb volume was measured using an optoelectronic limb volumeter. Patients using compression stockings were advised to remove stockings 2 h prior to their appointment. Measurements were taken with the patient seated and the affected leg in a horizontal position. Five readings were taken before and after device usage at Week 0 and Week 6 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alun Davies, MA DM FRCS FHEA | Imperial College London and Imperial College London NHS Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Academic Department of Vascular Surgery, Charing Cross Hospital | London | W4 8RF | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27919609 | Result | Ravikumar R, Williams KJ, Babber A, Lane TRA, Moore HM, Davies AH. Randomised Controlled Trial: Potential Benefit of a Footplate Neuromuscular Electrical Stimulation Device in Patients with Chronic Venous Disease. Eur J Vasc Endovasc Surg. 2017 Jan;53(1):114-121. doi: 10.1016/j.ejvs.2016.09.015. Epub 2016 Dec 2. |
Not provided
Not provided
Data available on request.
12 Months after publication of main study
From listed authors.
Not provided
Patient stayed in the full length of the study. Chronic venous insufficiency (C2-C5 CEAP). Blood pressure <160/100mmHg. No current foot ulceration
Recruitment from vascular outpatients clinic between 20/02/2014 - 18/09/2014.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | REVITIVE IX: Actual Device | Trial participants will receive the true Revitive IX device REVITIVE IX: neuromuscular electrical stimulation device |
| FG001 | REVITIVE IX: Sham Device | Trial participants will receive a sham device REVITIVE IX: sham device |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Test Device | Patients received the REVITIVE IX device for 6 weeks of home usage. |
| BG001 | Sham Device | Sham REVITIVE IX for 6 weeks of home usage. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV | Femoral vein haemodynamics is measured using ultrasound scan - Time Averaged Mean Velocity | Posted | Mean | Standard Deviation | percentage change | 0 and 6 weeks |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | REVITIVE IX: Actual Device | Trial participants will receive the true Revitive IX device REVITIVE IX: neuromuscular electrical stimulation device |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr Tristan Lane | Imperial College London | 02033117317 | tristan.lane@imperial.ac.uk |
Not provided
| ID | Term |
|---|---|
| D014689 | Venous Insufficiency |
| D004487 | Edema |
| D014648 | Varicose Veins |
| D054070 | Postthrombotic Syndrome |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 0 and 6 weeks |
| Clinical Symptoms | Change in clinical symptoms as assessed by the Venous Clinical Severity Score (VCSS) from 0 to 6 weeks, lower score means improvement. Maximum score on VCSS is 30. Minimum score is 0. | 0 and 6 weeks |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Secondary | Changes in Limb Swelling, Volume | Lower limb oedema measured before and after using the device at 0 and 6 weeks using a perimeter. Limb volume was measured using an optoelectronic limb volumeter. Patients using compression stockings were advised to remove stockings 2 h prior to their appointment. Measurements were taken with the patient seated and the affected leg in a horizontal position. Five readings were taken before and after device usage at Week 0 and Week 6 | Posted | Mean | Standard Deviation | ml | 0 and 6 weeks |
|
|
|
|
| Secondary | Clinical Symptoms | Change in clinical symptoms as assessed by the Venous Clinical Severity Score (VCSS) from 0 to 6 weeks, lower score means improvement. Maximum score on VCSS is 30. Minimum score is 0. | Posted | Mean | Standard Deviation | Percentage change in VCSS score | 0 and 6 weeks |
|
|
|
|
| 0 |
| 11 |
| 0 |
| 11 |
| 0 |
| 11 |
| EG001 | REVITIVE IX: Sham Device | Trial participants will receive a sham device REVITIVE IX: sham device | 0 | 11 | 0 | 11 | 0 | 11 |
Not provided
Not provided
Not provided
| D020246 | Venous Thrombosis |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| week 6 prestimulation |
|
| week 6 post stimulation |
|
| 0.0815 |
| Superiority |